Biotek-snakken — Marts 2024
-
Novo har også et program der går efter samme target. Så man kan nok forvente flere søger det space efter oral small molecue muligheder
-
Investeringspodcasten 214: Novo Nordisk split, GN Store Nord, NVIDIA, Demant, renter & Japan. https://www.proinvestor.com/boards/119435
-
Kort video: Speedsnak om FED og fedmemedicin..Her tager Helge Larsen temperaturen på Novo Nordisk, Zealand Pharma og ikke mindst Gubra, som er blevet en vældig populær aktie inden for den seneste måned og især de sidste par dage. Han kommer også med nogle advarsler, der er gode at tage med sig generelt, når man investerer i biotek. https://www.proinvestor.com/boards/119446
-
William Blair's Andy Hsieh - VK2735 kan ende op med at være en forbedret version af Tirzepatide.
https://www.biotechtv.com/post/andy-hsieh-march-21-2024
Snak om Viking starter 8:45 minutter inde i indslaget. -
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://www.proinvestor.com/investornyt/1135280/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Where Will Viking Therapeutics Stock Be in 10 Years?
Viking Therapeutics (NASDAQ: VKTX) now ranks among the hottest biotech stocks on the market. The company's announcement in February of positive results from its phase 2 study of experimental weight loss drug VK2735 provided a huge catalys https://www.proinvestor.com/investornyt/1135788/where-will-viking-therapeutics-stock-be-in-10-years
-
Is Viking Therapeutics Stock a Millionaire Maker? https://www.proinvestor.com/investornyt/1135925/is-viking-therapeutics-stock-a-millionaire-maker
-
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics? https://www.proinvestor.com/investornyt/1136593/best-obesity-drug-stock-eli-lilly-novo-nordisk-or-viking-therapeutics
-
-
Zai Lab Partner Novocure's Metis Phase 3 Trial Meets Primary Endpoint In Brain Metastases https://www.proinvestor.com/investornyt/1137338/zai-lab-partner-novocures-metis-phase-3-trial-meets-primary-endpoint-in-brain-metastases
-
Aldeyra preps rebound bid for dry-eye hopeful reproxalap https://firstwordpharma.com/story/5841474?from=article
-
Aeovian moves seizure candidate into the clinic, raises $50M
AV078 is an mTORC1 inhibitor in development for tuberous sclerosis complex (TSC) epilepsy. https://firstwordpharma.com/story/5841451?from=article -
Akebia gets FDA approval of renal anaemia therapy Vafseo https://firstwordpharma.com/story/5841297?from=article
-
Arcadia Biosciences (RKDA) Reports Q4 Loss, Misses Revenue Estimates https://www.proinvestor.com/investornyt/1138130/arcadia-biosciences-rkda-reports-q4-loss-misses-revenue-estimates
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind